Hierro-Bujalance et al.(2020) showed that empagliflozin (EMP) reduced senile plaque density and the levels of soluble and insoluble amyloid β (Aβ) in the cortex and hippocampus of treated mice in APP/PS1xd/db model (model resembling actual AD pathology). The gene discussed is APP; the disease is Alzheimer disease.